When will Elacestrant be available on the market?

The availability of Elacestrant in various regions around the world varies. According to the latest information, elastran has been approved by many countries and regions in 2023 and has become an important drug in the treatment of breast cancer.

In the United States, elastran was approved by the U.S. FDA on January 27, 2023, under the trade name ORSERDU. This approval brings new treatment options to the U.S. market for patients with ER+, HER2- advanced or metastatic breast cancer, particularly those with ESR1 mutations. The FDA's approval marks an important milestone in the clinical application of elastran, becoming a new option for the treatment of endocrine therapy-resistant breast cancer.

In Europe, elastran was also approved by the European Medicines Agency (EMA) on September 15, 2023. The trade name is also Orserdu. This approval provides more treatment options for breast cancer patients in the European market, especially those whose disease has progressed after receiving endocrine therapy. With the approval of the European Union, the applicable population of elastran has been further expanded, which is expected to bring hope to more patients.

However, in the Chinese market, elastran is not yet available on the market and is still in the approval stage. Chinese breast cancer patients, especially those with ESR1 mutations, still have to wait for the introduction of this drug. Considering the successful application of elastran in the European and American markets and its remarkable efficacy in patients with breast cancer that is resistant to endocrine therapy, it is expected that this drug will be approved in China in the next few years.

In addition to the original drug, generic versions of elastran are also gradually appearing on the market. Laos' Lucius Pharmaceuticals (Lucius) has launched a generic version of elastran called LuciElace, which provides patients with more economical options. The launch of generic drugs is expected to further reduce treatment costs and enable more patients to benefit.

Reference materials：https://www.drugs.com/mtm/elacestrant.html